Can a single drug keep a rare blood vessel disease at bay?
NCT ID NCT00748644
First seen Nov 20, 2025 · Last updated Jun 12, 2026 · Updated 23 times
Summary
This study looked at whether rituximab, a targeted antibody therapy, works better than the standard drug azathioprine for preventing major relapses in people with ANCA-associated vasculitis (inflammation of blood vessels). 117 adults who were already in remission after initial treatment took part. The goal was to see which drug kept the disease under control longer with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.